Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Mama Bear who wrote (1104)	6/16/1998 5:09:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 4634

<<All stocks that are not listed on the NYSE or ASE are technically traded over the counter. It's a sniggling little detail at best.>> So you are saying that there is no distinction nor any more stringemt requirements from NASDAQ to be listed on the National Market? <<Oh right, like any but the most feeble don't know he's short.>> That does not matter. Using the same logic one should not require disclosure of any type for any investment. <<I never looked at BTIM. But if I had to bet, I'd bet that Asensio is 100% accurate in his assessment of the company. He's just been right too many times before to bet against it.>> Which is PRECISELY my point. His words move the market in his favor even if he is wrong. BTW, Abbott Labs is throwing 3M to Biotime for marketing and manufacturing rights. Seems an odd thing to do for what Asensio describes as a dwindling 30M total market for such products. It also seems odd that the insiders are still buying and none have sold. From a technical standpoint I was wrong on BTIM. I felt it had strong support at 10-11 (which was where it was when Asensio re-iterated his previous proclamation). On face value though I think his arguments on this one are weak and misguided. Hextend has been proven to be demonstrably better than the equivalents on the market today. Jim